Somatropin oral

Drug Profile

Somatropin oral

Alternative Names: HanTropin; hGH - HanAll BioPharma; HL 032; Oral hGH - HanAll Biopharma; Resist-hGH; Vitatropin

Latest Information Update: 13 Jan 2016

Price : $50

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Somatotropin deficiency

Most Recent Events

  • 13 Jan 2016 Phase I development is ongoing in South Korea
  • 16 Jul 2013 Biomarkers information updated
  • 31 Jan 2012 HanAll BioPharma completes a phase I trial in Somatotropin deficiency in South Korea (NCT01440686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top